Mutant MHC class II epitopes drive therapeutic immune responses to cancer

Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patie...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nature
Main Authors: Kreiter, Sebastian, Vormehr, Mathias, van de Roemer, Niels, Diken, Mustafa, Löwer, Martin, Diekmann, Jan, Boegel, Sebastian, Schrörs, Barbara, Vascotto, Fulvia, Castle, John C., Tadmor, Arbel D., Schoenberger, Stephen P., Huber, Christoph, Türeci, Özlem, Sahin, Ugur
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4838069/
https://ncbi.nlm.nih.gov/pubmed/25901682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature14426
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares